No Data
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $23
Wells Fargo analyst Larry Biegelsen maintains $Bausch + Lomb Corp.(BLCO.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 60.1
Bausch + Lomb INFUSE for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily
Bausch + Lomb Launches Blink NutriTears Clinically Proven Nutritional Supplement for Dry Eyes in the United States
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter
Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors
Express News | Bausch + Lomb Announced Earlier Health Canada Approved Its EnVista Envy Full Visual Range Intraocular Lens
Bausch + Lomb Presents New Scientific Data And Evaluations Featuring Consumer, Vision Care And Pharmaceutical Products At Optometry's Meeting June 19-22, 2024
15 ePosters and In-Person Presentations Will Include Clinical Data on Blink NutriTears Supplement for Dry Eyes, Blink Triple Care Lubricating Eye Drops and MIEBO (Perfluorohexyloctane Ophthalmic Solut
Benjamin’s : New CEO